NEW YORK, Jan. 19, 2023 (GLOBE NEWSWIRE) – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) continues its investigation into allegations made on behalf of investors in Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”). YMAB Share. A complaint has been filed on behalf of investors who acquired Y-mAbs common stock in the open market or pursuant to registration statements filed with the US Securities and Exchange Commission (“SEC”) during the period October 6, 2020 to October 6, 2020 have October 28, 2022 inclusive (the “Class Period”).

If you purchased Y-mAbs common stock during the Class Period and would like to discuss this case, please contact us via email jcampisi@kaplanfox.com or by calling (212) 329-8571 or via click here.

If you are a member of the proposed class, you can move the court by March 20, 2023 at the latest to serve as lead plaintiff for the alleged class. If you have losses, we encourage you to contact us to learn more about the Lead Plaintiff Proceedings. You do not have to aspire to become Lead Plaintiff to participate in a possible recovery.

The Complaint alleges that the U.S. Food and Drug Administration released its briefing document for the Advisory Committee meeting regarding the Company’s Biologics License Application (“BLA”) for omburtamab for the treatment of on October 26, 2022, shortly after the date of market opening has pediatric patients with CNS/leptomeningeal metastases from neuroblastoma. The complaint further alleges that the FDA’s review team identified three key issues with the application submitted by Y-mAbs in the briefing document. According to the complaint, on October 26, 2022, Y-mAbs’ stock price fell $4.16 per share (from $15.17 to $11.01) as a result of the disclosure of true facts in the FDA’s briefing document. On October 28, 2022, after the close of trading, Y-mAbs filed a Form 8-K with the SEC informing investors that the AdCom had voted 16-0 that Y-mAbs had not provided sufficient evidence, to close …